Our results also shed light on guiding the development of therapeutic strategies using the SRC-3 inhibitor, SI-2, for MM patients with t(4;14) translocations or induced RR from proteasome-inhibitor therapy. Here, NCOA3 is linked to Miyoshi myopathy.